Hypophosphatemia in a Specialized Intestinal Failure Unit: An Observational Cohort Study.
enteral nutrition
hypophosphatemia
intestinal failure
parenteral nutrition
Journal
JPEN. Journal of parenteral and enteral nutrition
ISSN: 1941-2444
Titre abrégé: JPEN J Parenter Enteral Nutr
Pays: United States
ID NLM: 7804134
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
28
07
2020
received:
09
06
2020
accepted:
17
08
2020
pubmed:
26
8
2020
medline:
3
11
2021
entrez:
26
8
2020
Statut:
ppublish
Résumé
Patients with intestinal failure (IF) are prone to hypophosphatemia and shifts in magnesium and potassium levels. Although these shifts are often attributed to refeeding syndrome (RFS), the incidence of electrolyte shifts among patients with IF is unknown. We evaluated the occurrence of hypophosphatemia and other electrolyte shifts according to the functional and pathophysiological IF classifications. We consecutively included all patients' first admission to an IF unit from 2013 to 2017. Electrolyte shifts were defined as severe hypophosphatemia <0.6 mmol/L (mM) or any 2 other shifts below reference range, comprising hypomagnesemia <0.75 mM, hypophosphatemia <0.8 mM, or hypokalemia <3.5 mM. Outcomes included length of stay, central line-associated bloodstream infection, and other infections. Mortality was evaluated 6 months after discharge. Of 236 patients with IF, electrolyte shifts occurred in 99 (42%), and 127 (54%) of these patients received intravenous supplementation with either phosphate, magnesium, or potassium. In patients who started parenteral nutrition, up to 62% of early-onset shifts (<5 days) related to refeeding, and up to 63% of late-onset shifts (≥5 days) could be ascribed to infections. Derangements occurred in 7 (18%) with type 1 IF, 53 (43%) with type 2 IF, and 39 (53%) readmitted patients with type 3 IF. Of 133 patients with IF secondary to short-bowel syndrome, 65 (49%) developed shifts. In patients with IF, electrolyte shifts are frequent but not always due to RFS. Electrolyte shifts are common in patients with type 2 and those readmitted with type 3 IF.
Sections du résumé
BACKGROUND
Patients with intestinal failure (IF) are prone to hypophosphatemia and shifts in magnesium and potassium levels. Although these shifts are often attributed to refeeding syndrome (RFS), the incidence of electrolyte shifts among patients with IF is unknown. We evaluated the occurrence of hypophosphatemia and other electrolyte shifts according to the functional and pathophysiological IF classifications.
METHODS
We consecutively included all patients' first admission to an IF unit from 2013 to 2017. Electrolyte shifts were defined as severe hypophosphatemia <0.6 mmol/L (mM) or any 2 other shifts below reference range, comprising hypomagnesemia <0.75 mM, hypophosphatemia <0.8 mM, or hypokalemia <3.5 mM. Outcomes included length of stay, central line-associated bloodstream infection, and other infections. Mortality was evaluated 6 months after discharge.
RESULTS
Of 236 patients with IF, electrolyte shifts occurred in 99 (42%), and 127 (54%) of these patients received intravenous supplementation with either phosphate, magnesium, or potassium. In patients who started parenteral nutrition, up to 62% of early-onset shifts (<5 days) related to refeeding, and up to 63% of late-onset shifts (≥5 days) could be ascribed to infections. Derangements occurred in 7 (18%) with type 1 IF, 53 (43%) with type 2 IF, and 39 (53%) readmitted patients with type 3 IF. Of 133 patients with IF secondary to short-bowel syndrome, 65 (49%) developed shifts.
CONCLUSION
In patients with IF, electrolyte shifts are frequent but not always due to RFS. Electrolyte shifts are common in patients with type 2 and those readmitted with type 3 IF.
Identifiants
pubmed: 32841404
doi: 10.1002/jpen.2006
pmc: PMC8451901
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1259-1267Informations de copyright
© 2020 American Society for Parenteral and Enteral Nutrition.
Références
Ann Clin Biochem. 2015 Jan;52(Pt 1):82-7
pubmed: 24609720
Int J Eat Disord. 2015 Nov;48(7):866-73
pubmed: 25625572
J Clin Med. 2019 Dec 13;8(12):
pubmed: 31847205
Eur J Gastroenterol Hepatol. 2018 Nov;30(11):1270-1276
pubmed: 29994872
JPEN J Parenter Enteral Nutr. 2005 Mar-Apr;29(2):108-17
pubmed: 15772389
Nutrition. 2004 Apr;20(4):346-50
pubmed: 15043849
Am J Infect Control. 2011 May;39(4 Suppl 1):S1-34
pubmed: 21511081
Nutr Clin Pract. 2012 Oct;27(5):689-94
pubmed: 22683565
J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:113-7
pubmed: 24251716
Clin Nutr ESPEN. 2020 Aug;38:253-262
pubmed: 32690166
Clin Nutr. 2015 Feb;34(1):134-9
pubmed: 24612924
Nutrition. 2018 Mar;47:13-20
pubmed: 29429529
Clin Kidney J. 2012 Feb;5(Suppl 1):i3-i14
pubmed: 26069819
JPEN J Parenter Enteral Nutr. 1990 Jan-Feb;14(1):90-7
pubmed: 2109122
Arch Surg. 1996 Oct;131(10):1043-7
pubmed: 8857900
Clin Nutr. 2017 Feb;36(1):49-64
pubmed: 27642056
Nutrition. 2017 Mar;35:151-160
pubmed: 28087222
Clin Nutr. 2015 Apr;34(2):171-80
pubmed: 25311444
Nutrition. 2010 Feb;26(2):156-67
pubmed: 20122539
Clin Exp Gastroenterol. 2018 Jul 10;11:255-264
pubmed: 30022846
JPEN J Parenter Enteral Nutr. 2017 May;41(4):566-574
pubmed: 26488457
Clin Nutr. 2003 Jun;22(3):235-9
pubmed: 12765661
Endocr Connect. 2018 Apr;7(4):R135-R146
pubmed: 29540487
Aliment Pharmacol Ther. 2006 Jul 1;24(1):19-31
pubmed: 16803600
Clin Nutr. 2011 Jun;30(3):365-8
pubmed: 21256638
Best Pract Res Clin Gastroenterol. 2016 Apr;30(2):173-85
pubmed: 27086884
Nutrition. 2001 Jul-Aug;17(7-8):632-7
pubmed: 11448586
Clin Nutr. 2019 Aug;38(4):1828-1832
pubmed: 30086999
Nutrition. 2014 Nov-Dec;30(11-12):1448-55
pubmed: 25280426
Aliment Pharmacol Ther. 2013 Mar;37(6):587-603
pubmed: 23331163
Pharm World Sci. 2008 Aug;30(4):329-35
pubmed: 18373276
BMJ Open. 2013 Jan 11;3(1):
pubmed: 23315514
Lancet. 2019 Jun 8;393(10188):2312-2321
pubmed: 31030981
BMJ. 2013 Nov 11;347:f6570
pubmed: 24217269
Eur J Clin Nutr. 2008 Jun;62(6):687-94
pubmed: 17700652
Int J Eat Disord. 2014 Mar;47(2):148-56
pubmed: 24375513